Carbon Collective Climate Solutions U.S. Equity ETF (NASDAQ: CCSO)

Dernières nouvelles pour Carbon Collective Climate Solutions U.S. Equity ETF (NASDAQ:CCSO)

Carbon Collective Climate Solutions U.S. Equity ETF

Industrials

Energy

Basic Materials

Consumer Cyclical

Technology

Utilities

Other

Financial Services

Real Estate

Consumer Defensive

To pursue its objective, the Fund will invest at least 80 percent of its net assets, plus borrowings for investment purposes, in U.S.-listed equity securities of Climate Solution Companies. The Funds 80 percent policy is non-fundamental and can be changed without shareholder approval. However, Fund shareholders would be given at least 60 days notice prior to any such change. The Fund may invest in international companies, including those in emerging markets, through U.S. exchange-traded American Depositary Receipts (ADRs), however, they will not be considered U.S. equity securities for purposes of the Funds 80 percent policy. The Fund intends that under normal circumstances substantially all of its net assets will be invested in equity securities.

Tesla Inc.

Waste Connections Inc

Carrier Global Corp.

Waste Mgmt Del

Johnson Controls Internation S

Nucor Corporation

Southern Copper Corp

Quanta Services Inc

First Solar Inc

Li Auto Inc. (ADR)

Republic Services Inc

Ge Vernova Inc Usd 0.01

Cameco Corporation Com Npv

Carbon Collective Climate Solutions US Equity ETF

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Gerald Pascarelli initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Hold rating. Turning Point Brands shares closed at $82.94 on Thursday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Luke Sergott initiated coverage on Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with an Overweight rating and announced a price target of $90. Incyte shares closed at $74.89 on Thursday. <a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying INCY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-1024x571.png" alt="" class="wp-image-1010888" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

News

Initiation

Markets

Analyst Ratings

Trading Ideas

INCY

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

WIIM

PSO stock has given up its prior loss. Pearson shares were trading lower after the company reported a year-over-year decrease in H1 financial results.

Macro Economic Events

Economics

Federal Reserve

Reuters Reporting Fed's Hammack Says Fed Sees Pressure On Inflation Side Of Mandate With Inflation Continuing To Influence Economic Decisions; Tariff Passthrough To Prices And Weakness In Job Market Into End Of Year

HOLX

HOLX stock has given up its prior gain. Hologic shares were trading higher after Morgan Stanley and UBS raised their respective price targets on the stock.

Raymond James analyst Melissa Fairbanks reiterates Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Outperform and raises the price target from $720 to $875.

Price Target

Reiteration

MPWR

Raymond James Reiterates Outperform on Monolithic Power Systems, Raises Price Target to $875

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst Shrenik Kothari downgraded the rating for CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) from Outperform to Neutral and maintained the price target of $460. CyberArk Software shares closed at $411.47 on Thursday. <a href="https://www.benzinga.com/quote/cybr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Lizzie Dove downgraded Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) from Neutral to Sell and raised the price target from $87 to $105. Avis Budget shares closed at $170.24 on Thursday. <a href="https://www.benzinga.com/quote/car/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Michael Ciarmoli downgraded Albany International Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) from Buy to Hold and slashed the price target from $70 to $55. Albany International shares closed at $54.19 on Thursday. <a href="https://www.benzinga.com/quote/ain/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David Manthey downgraded Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) from Outperform to Neutral and cut the price target from $145 to $130. Builders FirstSource shares closed at $127.13 on Thursday. <a href="https://www.benzinga.com/quote/BLDR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Aaron Kimson downgraded Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) from Market Outperform to Market Perform and maintained the price target of $95. Procore Technologies shares closed at $71.63 on Thursday. <a href="https://www.benzinga.com/quote/PCOR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYBR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CYBR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-1024x591.png" alt="" class="wp-image-1010876" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Downgrades

BLDR

CYBR

PCOR

This CyberArk Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Raymond James analyst Frank Louthan maintains Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) with a Outperform and raises the price target from $4.5 to $5.

LUMN

Raymond James Maintains Outperform on Lumen Technologies, Raises Price Target to $5

Raymond James analyst Srini Pajjuri reiterates KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Outperform and raises the price target from $850 to $950.

KLAC

Raymond James Reiterates Outperform on KLA, Raises Price Target to $950

Barclays analyst Brandt Montour maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Overweight and raises the price target from $25 to $31.

NCLH

Barclays Maintains Overweight on Norwegian Cruise Line, Raises Price Target to $31

Wedbush analyst Alicia Reese maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and raises the price target from $142 to $165.

RBLX

Wedbush Maintains Outperform on Roblox, Raises Price Target to $165

On Friday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.57</a>.
The&nbsp;company reported sales&nbsp;of $3.68 billion, up 4% year over year, beating the <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46785919/regeneron-pharmaceuticals-likely-to-report-lower-q2-earnings-these-most-accura" rel="noreferrer noopener">consensus of $3.29 billion</a>.
In the second quarter, U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;decreased 25% year-over-year to $1.15&nbsp;billion, including $393 million from Eylea HD and $754 million from Eylea.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Net product sales of Eylea HD increased in the second quarter of 2025, compared to the second quarter of 2024, due to higher sales volumes driven by increased demand.
Net product sales of EYLEA were negatively impacted by lower sales volumes due to continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, continued transition of patients to EYLEA HD, and a lower net selling price.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased, due to the company&#8217;s share of profits from the commercialization of antibodies, which were $1.282 billion and $988&nbsp;million in the second quarter of 2025 and 2024, respectively.
The change in the company&#8217;s share of profits from the commercialization of antibodies was driven by higher profits associated with an increase in Dupixent sales.
<h2 class="wp-block-heading">Pipeline Update</h2>
In its earnings press release, Regeneron said it expects regulatory approvals to be delayed for its currently pending U.S. Food and Drug Administration (FDA) applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for macular edema following retinal vein occlusion), which have <a target="_blank" href="https://www.benzinga.com/pressreleases/25/08/g46788448/regeneron-reports-second-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">PDUFA dates in August 2025</a>.
The anticipated delay concerns observations from an FDA general site inspection at the filler for EYLEA HD in these regulatory applications, Catalent Indiana LLC, recently acquired by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
The inspection was completed in mid-July and was not specific to EYLEA HD. Novo has communicated with the FDA and expects to submit its response next week.
Based on the company&#8217;s review of the observations, Novo&#8217;s proposed response to the FDA, and the progress the company has made with alternate third-party fillers, the company anticipates an expeditious resolution of the filling issues for EYLEA HD.
The FDA issued a Complete Response Letter (CRL) for the application for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent site inspection.
<h2 class="wp-block-heading">Outlook</h2>
Regeneron expects a 2025 GAAP gross margin of approximately 83%, compared to the <a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">prior guidance of 83%–84%</a>.
The company expects an adjusted gross margin of approximately 86%, compared to the&nbsp;prior guidance of 86%–87%.
Price Action:&nbsp;REGN stock is trading higher by 3.77% to $566 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46789863/amazon-post-earnings-decline-totally-wrong-says-analyst-as-ceo-points-out-aws-has-more-demand-than-we-have-capacity" target="_blank" rel="noreferrer noopener">Amazon Post-Earnings Decline &#8216;Totally Wrong,&#8217; Says Analyst As CEO Points Out AWS Has &#8216;More Demand Than We Have Capacity&#8217;</a></li>
</ul>
Photo by Marianne Campolongo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

REGN

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

Barclays analyst Ross Sandler maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $640 to $810.

Barclays Maintains Overweight on Meta Platforms, Raises Price Target to $810

Raymond James analyst Srini Pajjuir reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $230 to $240.

AAPL

Raymond James Reiterates Outperform on Apple, Raises Price Target to $240

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $180 to $225.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $225

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and raises the price target from $77 to $78.

Barclays Maintains Overweight on Masco, Raises Price Target to $78

Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $52 to $50.

APLS

Raymond James Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $50

<ul>
<li>UNH</li>
<li>AMZN</li>
<li>FIG</li>
<li>GLD</li>
<li>NVDA</li>
<li>RDDT</li>
<li>AAPL</li>
<li>TSLA</li>
<li>AMD</li>
<li>META</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AMZN

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of Aug. 1, 2025 (Via Swaggy Stocks)

Barclays analyst Benjamin Budish maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Overweight and raises the price target from $460 to $463.

LPLA

Barclays Maintains Overweight on LPL Finl Hldgs, Raises Price Target to $463

MCVT

Mill City Ventures Establishes $500M Equity Line Agreement With Alliance Global Partners To Advance SUI Treasury Strategy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler analyst Brent Bracelin upgraded the rating for AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) from Neutral to Overweight and raised the price target from $240 to $350. AppFolio shares closed at $267.38 on Thursday. <a href="https://www.benzinga.com/quote/appf/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Ken Newman upgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Sector Weight to Overweight and announced a $50 price target. Cognex shares closed at $40.77 on Thursday. <a href="https://www.benzinga.com/quote/cgnx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Noah Zatzkin upgraded the rating for THOR Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) from Underweight to Sector Weight. Thor Industries shares closed at $90.99 on Thursday. <a href="https://www.benzinga.com/quote/tho/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Ike Boruchow upgraded Canada Goose Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#TSX">GOOS</a>) from Equal-Weight to Overweight and raised the price target from C$19 to C$20. <a href="https://www.benzinga.com/quote/goos/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying APPF stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/APPF/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-1024x557.png" alt="" class="wp-image-1010863" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01091628/image-10.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Comments

Carbon Collective Climate Solutions U.S. Equity ETF

Actualités

Dernières nouvelles pour Carbon Collective Climate Solutions U.S. Equity ETF (NASDAQ:CCSO)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL